Roche says that it has closed its 235 million Swiss-franc purchase of privately-held Swiss biotechnology company, GlycArt.

The deal, which was announced earlier this month [[19/07/05d]], brings Roche three monoclonal antibodies currently in pre-clinical development for the treatment of cancer, as well as the “GlycoMAb glycosylation” technology, which improves the cancer-killing potential of drugs. Roche claims that the technology has “the potential to generate best-in- class antibody therapeutics in disease areas such as oncology” and it will no doubt give Roche a further boost in a therapeutic area in which it is already a significant force.